A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene ...

Knowable Magazine reports on advancements in pancreatic cancer treatment, including new drugs, vaccines, and early diagnostic ...

Responsible for nearly 10 million deaths worldwide in 2020, cancer consistently ranks among the leading causes of death each year. Brought on by genetic mutations and external risk factors, cancer is ...

The deadliest cancers just met their match. A revolutionary cancer vaccine prevents the devastating relapses that have made KRAS-mutated tumors nearly impossible to cure, offering genuine hope to ...

The University of Cincinnati Cancer Center’s Tom Cunningham has received a two-year, $150,000 grant from the Lung Cancer Research Foundation (LCRF) to test approaches to neutralize an enzyme complex ...

A research team at the Medical University of Vienna has discovered a new approach to treating a particularly frequent and ...

The phase 3 KANDLELIT-007 trial (NCT07190248) evaluating the KRAS G12C inhibitor calderasib (MK-1084) plus subcutaneous pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex; SC pembrolizumab) ...

The drug is not considered a cure, but results emerging from clinical trials point to the first major advancement in decades for a devastating cancer.

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...

Even after surgery and chemotherapy, some cancers, like pancreatic and colorectal, maintain a foothold in the body and ...